EU Regulator Reviews Novartis MS Pill
Wall Street Journal
By STEN STOVALL And JENNIFER CORBETT DOOREN LONDON—Europe's drug regulator Friday said it is reviewing the "benefits and risks" of Novartis AG's multiple-sclerosis drug Gilenya and recommended doctors closely monitor the hearts of patients after they ...
See all stories on this topic »

MS drug investigated after 11 patients die
Columbus Dispatch
Associated Press Saturday January 21, 2012 7:13 AM LONDON -- A multiple-sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died. The drug, Gilenya, was licensed last year in the European ...
See all stories on this topic »

Multiple sclerosis: BIIB's Tysabri gets FDA OK on test, label change
MedCity News
Multiple sclerosis patients using Biogen Idec (NASDAQ:BII drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain infection that affects some patients using the drug. ...
See all stories on this topic »

MS Drug Gilenya Under Safety Review
KGTV San Diego
By Georgiann CarusoCNN (CNN) -- Health agencies on both sides of the Atlantic are investigating reports of 11 deaths in multiple sclerosis patients taking Gilenya, the first multiple sclerosis drug approved in pill form. ...
See all stories on this topic »

Marco Nannini links his Global Ocean Race campaign to Multiple Sclerosis
BYM News (press release)
During the GOR's Leg 2 from Cape Town, South Africa, to Wellington an online donation received by Nannini and Ramon has led directly to some extra branding on their Class40's hull and a strong link to the Wellington Multiple Sclerosis Society; ...
See all stories on this topic »

Eleven deaths reported after taking MS drug
allvoices
By Debbie Nicholson Concerns are being raised over Gilenya, the first oral drug for relapsing forms of multiple sclerosis in adults. Today the European Medicines Agency in a statement that the drug Gilenya may harm the heart. The FDA is also reviewing ...
See all stories on this topic »